Reinaldo M. Diaz has served on our board of directors since January 2017. Mr. Diaz serves has served as the chief executive officer of Opna Immuno-Oncology S.A., or Opna, since December 2023 and previously served as the chief business officer of Opna from May 2020 to November 2023. Mr. Diaz served as venture partner at Longitude Capital Management Co., LLC, or Longitude, a venture capital firm focusing on healthcare companies, from November 2015 to December 2023, and beginning in January 2024, serves as an industry advisor to Longitude. Mr. Diaz has served as the managing member and managing director of DA Advisors, LLC, a financial and strategic consulting company focusing on biopharmaceutical companies, since 2005. Mr. Diaz served as a managing director at Auven Therapeutics, a private equity firm focusing on life sciences, from 2008 to 2018. Mr. Diaz served as managing member and co-founder of Diaz & Altschul Capital Management, LLC, an asset management firm focusing on healthcare companies, from 1996 to 2005. Mr. Diaz served as managing director and head of the healthcare group at Schroder Wertheim & Co., Inc. from 1993 to 1996. Mr. Diaz served in various roles at PaineWebber Development Corporation from 1985 to 1993, including as president from 1990 to 1993. Mr. Diaz is currently on the board of directors of Lexeo Therapeutics, Inc., a publicly traded biotechnology company. Mr. Diaz received a B.A. in general studies from Harvard University and an M.B.A. from Harvard Business School.
